211 related articles for article (PubMed ID: 36448591)
1. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
Chang CH; Lu CH; Chung CH; Su SC; Kuo FC; Liu JS; Li PF; Huang CL; Chen KC; Ho LJ; Kuo CC; Chang CY; Lin MS; Liu YC; Chu NF; Lee CH; Hung YJ; Hsieh PS; Lin FH; Hsieh CH; Chien WC
J Chin Med Assoc; 2022 Jul; 85(7):747-753. PubMed ID: 35648138
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
4. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
5. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
6. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
Xu L; Zheng XQ; Liao XX
Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer.
Saito A; Kitayama J; Horie H; Koinuma K; Kawashima R; Ohzawa H; Yamaguchi H; Kawahira H; Mimura T; Lefor AK; Sata N
Cancer Res Commun; 2021 Nov; 1(2):106-114. PubMed ID: 36860286
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D; Carstensen B; Elisabetta P; Lanzinger S; Tan EC; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Núñez J; Ha KH; Halvorsen S; Langslet G; Karasik A; Nyström T; Niskanen L; Guleria S; Klement R; Carrasco M; Foersch J; Shay C; Koeneman L; Hoti F; Farsani SF; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; ;
Cardiovasc Diabetol; 2023 Aug; 22(1):233. PubMed ID: 37653496
[TBL] [Abstract][Full Text] [Related]
14. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
15. Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus.
Choi Y; Ko SH; Chang K; Yoo KD; Ihm SH
J Diabetes; 2023 Nov; 15(11):944-954. PubMed ID: 37528628
[TBL] [Abstract][Full Text] [Related]
16. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
Nyström T; Toresson Grip E; Gunnarsson J; Casajust P; Karlsdotter K; Skogsberg J; Ustyugova A;
Diabetes Obes Metab; 2023 Jan; 25(1):261-271. PubMed ID: 36097728
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
[TBL] [Abstract][Full Text] [Related]
19. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
[TBL] [Abstract][Full Text] [Related]
20. Outcomes Associated With the Adjunctive Use of Dipeptidyl Peptidase-4 Inhibitors With Insulin Versus Other Antihyperglycemic Medications in Patients With Prediabetes or Diabetes After Cardiac Surgery.
Clark L; Weeda E; Griffin ML; Jones LA; Haney J
J Pharm Pract; 2021 Apr; 34(2):259-264. PubMed ID: 31409190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
